Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Dissociative

or Stimulant

& routes: Intranasal (under direct medical supervision)

Use the filters below to narrow your results.

None (1)

Spravato (1)

None (1)

Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

28 mg/device (each dose uses 2 devices) (1)

84 mg per session (1)

Within hours of first administration (1)

Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

~7-12 hours (1)

~48% intranasal (1)

Avoid; may cause fetal harm (1)

Rx, Schedule III (US). REMS program required. (1)

Showing below up to 1 result in range #1 to #1.

E

Esketamine

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"